Mesoblast is developing a series of high margin, off the shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Quote | Mesoblast Limited (NASDAQ:MESO)
Last: | $6.805 |
---|---|
Change Percent: | 0.0% |
Open: | $6.54 |
Close: | $6.805 |
High: | $6.87 |
Low: | $6.5 |
Volume: | 83,234 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Mesoblast Limited (NASDAQ:MESO)
2024-07-01 07:37:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We have the biggest pre-market stock movers that traders are going to want to start the week with on Monday morning! Moving stocks this morning are Roaring Kitty news, a company filing for ...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
Message Board Posts | Mesoblast Limited (NASDAQ:MESO)
Subject | By | Source | When |
---|---|---|---|
I think COmpany should have a look at | abrasivegritin | investorshub | 04/29/2023 11:09:49 AM |
5 day chart looks good, I'm in! | basssque | investorshub | 07/06/2022 7:04:11 PM |
How you doing | Docstemcell2020 | investorshub | 12/14/2021 8:05:59 PM |
Let's go Brando | Docstemcell2020 | investorshub | 10/26/2021 6:40:27 PM |
All of these RegMed stocks are scams | REAGAN | investorshub | 09/01/2021 9:45:55 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
2024-06-27 02:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...